Business
European GeneICE Patent Granted and CRT Trials ...
European GeneICE Patent Granted and CRT Trials ....
About this update from Valirx Plc
[{"type":"text","content":"\n \nFor immediate release: 07.00hrs 8 August 2007\n\n VALIRX PLC \n\n (\"ValiRx\") \n\n European GeneICE Patent Granted and CRT Trials Update \n\nValiRx (AIM: VAL), the cancer therapeutics company, today announces that its\nproprietary gene-silencing technology, GeneICE, has received patent approval by\nthe European Patent Office covering 23 European states*. This follows the\ngranting of a US patent in April 2007.\n\nValiRx holds the rights to GeneICE through its subsidiary, Cronos Therapeutics\nLtd (\"Cronos\"), which has an exclusive worldwide license agreement with\nImperial College Innovations.\n\nGeneICE compounds have the potential to freeze the development and growth of\ncancerous cells and also have potential major applications in inflammatory\ndisease and inherited genetic conditions. Cronos' partner, Cancer Research UK,\na prestigious research institute in Europe, is currently undertaking\npre-clinical trials on GeneICE through Cancer Research Technology Limited\n(\"CRT\").\n\nDr Satu Vainikka, CEO of ValiRx, commented:\n\n\"We are delighted to have received this European patent which makes the\ntechnology securely protected in the world's major life science markets: the US\nand Europe. We anticipate being able to update the market regarding the initial\nresults from CRT's pre-clinical trials on GeneICE in September.\"\n\n ---ENDS--- \n\nNotes to Editors\n\n* European countries include Austria, Belgium, Bulgaria, Switzerland, Cyprus,\nCzech Republic, Germany, Denmark, Estonia, Spain, Finland, France, the United\nKingdom, Greece, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Portugal,\nSweden, Slovakia and Turkey.\n\nInformation on ValiRx\n\nValiRx is a biopharmaceutical development company that is building a portfolio\nof complementary cancer-related therapeutic and diagnostic technologies. It\ncurrently holds stakes in Cronos and Morphogenesis Inc.:\n\n * Cronos holds licenses to two innovative and potentially market changing\n technologies, GeneICE and HyperGenomics, as well as having an extensive\n portfolio of pending and granted patents in the areas of gene regulation\n and epigenetic diagnostic technologies;\n \n * Morphogenesis Inc. is developing a portfolio of cell therapy products for\n the treatment of chronic disorders. Its most advanced product, being\n ImmuneFxâ„¢ for which it recently received a ...